Stock Track | Tempus AI Soars 5.40% Intraday on Expanded Bristol-Myers Squibb Partnership

Stock Track05-20

Tempus AI's stock soared 5.40% during intraday trading on Tuesday.

The rally was driven by the announcement of an expanded strategic collaboration with pharmaceutical giant Bristol-Myers Squibb. The two companies will deploy artificial intelligence, multimodal real-world data, and data science techniques across five initial clinical trial programs targeting solid tumor oncology, including lung, colon, and prostate cancers.

The initiative aims to optimize clinical trial designs and boost the success probability of key assets for Bristol-Myers Squibb. The deepened partnership validates the commercial capabilities of Tempus AI's platform, partially offsetting previous market concerns about equity dilution from a recent convertible bond offering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168475010?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 03:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168475010","market":"sg","top_or_hot":-1,"title":"Stock Track | Tempus AI Soars 5.40% Intraday on Expanded Bristol-Myers Squibb Partnership","media":"Stock Track","content":"<p>Tempus AI's stock soared 5.40% during intraday trading on Tuesday.</p><p>The rally was driven by the announcement of an expanded strategic collaboration with pharmaceutical giant Bristol-Myers Squibb. The two companies will deploy artificial intelligence, multimodal real-world data, and data science techniques across five initial clinical trial programs targeting solid tumor oncology, including lung, colon, and prostate cancers.</p><p>The initiative aims to optimize clinical trial designs and boost the success probability of key assets for Bristol-Myers Squibb. The deepened partnership validates the commercial capabilities of Tempus AI's platform, partially offsetting previous market concerns about equity dilution from a recent convertible bond offering.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tempus AI Soars 5.40% Intraday on Expanded Bristol-Myers Squibb Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tempus AI Soars 5.40% Intraday on Expanded Bristol-Myers Squibb Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-20 03:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tempus AI's stock soared 5.40% during intraday trading on Tuesday.</p><p>The rally was driven by the announcement of an expanded strategic collaboration with pharmaceutical giant Bristol-Myers Squibb. The two companies will deploy artificial intelligence, multimodal real-world data, and data science techniques across five initial clinical trial programs targeting solid tumor oncology, including lung, colon, and prostate cancers.</p><p>The initiative aims to optimize clinical trial designs and boost the success probability of key assets for Bristol-Myers Squibb. The deepened partnership validates the commercial capabilities of Tempus AI's platform, partially offsetting previous market concerns about equity dilution from a recent convertible bond offering.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1168475010","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168475010","pubTimestamp":1779220378,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tempus AI's stock soared 5.40% during intraday trading on Tuesday.The rally was driven by the announcement of an expanded strategic collaboration with pharmaceutical giant Bristol-Myers Squibb. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"个股追踪|扩大百时美施贵宝合作伙伴关系，腾邦AI盘中大涨5.40%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"Tempus AI's stock soared 5.40% during intraday trading on Tuesday.The rally was driven by the announcement of an expanded strategic collaboration with pharmaceutical giant Bristol-Myers Squibb. The two companies will deploy artificial intelligence, multimodal real-world data, and data science techniques across five initial clinical trial programs targeting solid tumor oncology, including lung, colon, and prostate cancers.The initiative aims to optimize clinical trial designs and boost the success probability of key assets for Bristol-Myers Squibb. The deepened partnership validates the commercial capabilities of Tempus AI's platform, partially offsetting previous market concerns about equity dilution from a recent convertible bond offering.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168475010","isCrawlerRequest":true}